tiprankstipranks
Trending News
More News >

Verve Therapeutics price target raised to $25 from $15 at H.C. Wainwright

H.C. Wainwright raised the firm’s price target on Verve Therapeutics (VERV) to $25 from $15 and keeps a Buy rating on the shares after the company reported Phase 1 data for its one-time gene editing treatment, VERVE-102, in patients with heterozygous familial hypercholesterolemia and/or premature coronary artery disease. Following the data, the firm is increasing its view on the probability of success for VERVE-102 to 55% from 40%, the analyst tells investors.

Confident Investing Starts Here:

Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>

Disclaimer & Disclosure

Looking for a trading platform? Check out TipRanks' Best Online Brokers , and find the ideal broker for your trades.

Report an Issue